Ming Zhang

Ming Zhang

Auto-generated profile, based on publicly available information

Ming Zhang

Global Health Institute, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2014 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
VMVadim Makarov
Vadim Makarov
BLBenoit Lechartier
Benoit Lechartier
MZMing Zhang
Ming Zhang
JNJoão Neres
João Neres
ASAstrid M van der Sar
Astrid M van der Sar
SCStewart T Cole
Stewart T Cole
The benzothiazinone lead compound, BTZ043, kills Mycobacterium tuberculosis by inhibiting the essential flavo‐enzyme DprE1, decaprenylphosphoryl‐beta‐D‐ribose 2‐epimerase. Here, we synthesized a new series of piperazine‐containing benzothiazinones (PBTZ) and show that, like BTZ043, the preclinical candidate PBTZ169 binds covalently to DprE1. The crystal structure of the DprE1‐PBTZ169 complex reveals formation of a semimercaptal adduct with Cys387 in the active site and explains the irreversible inactivation of the enzyme. Compared to BTZ043, PBTZ169 has improved potency, safety and efficacy in zebrafish and mouse models of tuberculosis (TB). When combined with other TB drugs, PBTZ169 showed additive activity against M. tuberculosis in vitro except with bedaquiline (BDQ) where synergy was observed. A new regimen comprising PBTZ169, BDQ and pyrazinamide was found to be more efficacious than the standard three drug treatment in a murine model of chronic disease. PBTZ169 is thus an attractive drug candidate to treat TB in humans.

1 June 2007 in Journal of Cell Science
Verified
Journal Article
Closed access
PDF file
SWShaoguang Wu
Shaoguang Wu
KRKi-Jong Rhee
Ki-Jong Rhee
MZMing Zhang
Ming Zhang
AFAugusto Franco
Augusto Franco
CSCynthia L. Sears
Cynthia L. Sears
Enterotoxigenic Bacteroides fragilis – organisms that live in the colon – secrete a metalloprotease toxin, B. fragilis toxin. This toxin binds to a specific intestinal epithelial cell receptor and stimulates cell proliferation, which is dependent, in part, on E-cadherin degradation and β-catenin–T-cell-factor nuclear signaling. γ-Secretase (or presenilin-1) is an intramembrane cleaving protease and is a positive regulator of E-cadherin cleavage and a negative regulator of β-catenin signaling. Here we examine the mechanistic details of toxin-initiated E-cadherin cleavage. B. fragilis toxin stimulated shedding of cell membrane proteins, including the 80 kDa E-cadherin ectodomain. Shedding of this domain required biologically active toxin and was not mediated by MMP-7, ADAM10 or ADAM17. Inhibition of γ-secretase blocked toxin-induced proteolysis of the 33 kDa intracellular E-cadherin domain causing cell membrane retention of a distinct β-catenin pool without diminishing toxin-induced cell proliferation. Unexpectedly, γ-secretase positively regulated basal cell proliferation dependent on the β-catenin–T-cell-factor complex. We conclude that toxin induces step-wise cleavage of E-cadherin, which is dependent on toxin metalloprotease and γ-secretase. Our results suggest that differentially regulated β-catenin pools associate with the E-cadherin–γ-secretase adherens junction complex; one pool regulated by γ-secretase is important to intestinal epithelial cell homeostasis.

18 December 2007 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
IRIan M Rosenthal
Ian M Rosenthal
MZMing Zhang
Ming Zhang
KWKathy N Williams
Kathy N Williams
CPCharles A Peloquin
Charles A Peloquin
STSandeep Tyagi
Sandeep Tyagi
ENEric L Nuermberger
Eric L Nuermberger
Availability of an ultra-short-course drug regimen capable of curing patients with tuberculosis in 2 to 3 mo would significantly improve global control efforts. Because immediate prospects for novel treatment-shortening drugs remain uncertain, we examined whether better use of existing drugs could shorten the duration of treatment. Rifapentine is a long-lived rifamycin derivative currently recommended only in once-weekly continuation-phase regimens. Moxifloxacin is an 8-methoxyfluoroquinolone currently used in second-line regimens. Using a well-established mouse model with a high bacterial burden and human-equivalent drug dosing, we compared the efficacy of rifapentine- and moxifloxacin-containing regimens with that of the standard daily short-course regimen based on rifampin, isoniazid, and pyrazinamide. Bactericidal activity was assessed by lung colony-forming unit counts, and sterilizing activity was assessed by the proportion of mice with culture-positive relapse after 2, 3, 4, and 6 mo of treatment. Here, we demonstrate that replacing rifampin with rifapentine and isoniazid with moxifloxacin dramatically increased the activity of the standard daily regimen. After just 2 mo of treatment, mice receiving rifapentine- and moxifloxacin-containing regimens were found to have negative lung cultures, while those given the standard regimen still harbored 3.17 log10 colony-forming units in the lungs (p < 0.01). No relapse was observed after just 3 mo of treatment with daily and thrice-weekly administered rifapentine- and moxifloxacin-containing regimens, whereas the standard daily regimen required 6 mo to prevent relapse in all mice. Rifapentine should no longer be viewed solely as a rifamycin for once-weekly administration. Our results suggest that treatment regimens based on daily and thrice-weekly administration of rifapentine and moxifloxacin may permit shortening the current 6 mo duration of treatment to 3 mo or less. Such regimens warrant urgent clinical investigation.

11 December 2019 in Nature
Verified
Journal Article
Closed access
LMLaura MacPherson
Laura MacPherson
JAJuliana Anokye
Juliana Anokye
MYMiriam M. Yeung
Miriam M. Yeung
ELEnid Y. N. Lam
Enid Y. N. Lam
YCYih-Chih Chan
Yih-Chih Chan
MDMark A. Dawson
Mark A. Dawson

1 August 2012 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
IRIan M. Rosenthal
Ian M. Rosenthal
RTRokeya Tasneen
Rokeya Tasneen
CPCharles A. Peloquin
Charles A. Peloquin
MZMing Zhang
Ming Zhang
DADeepak Almeida
Deepak Almeida
ENEric L. Nuermberger
Eric L. Nuermberger
In previous experiments, replacing the 10-mg/kg of body weight daily dose of rifampin with 7.5 to 10 mg/kg of rifapentine in combinations containing isoniazid and pyrazinamide reduced the duration of treatment needed to cure tuberculosis in BALB/c mice by approximately 50% due to rifapentine's more potent activity and greater drug exposures obtained. In the present study, we performed dose-ranging comparisons of the bactericidal and sterilizing activities of rifampin and rifapentine, alone and in combination with isoniazid and pyrazinamide with or without ethambutol, in BALB/c mice and in C3HeB/FeJ mice, which develop necrotic lung granulomas after infection with Mycobacterium tuberculosis . Each rifamycin demonstrated a significant increase in sterilizing activity with increasing dose. Rifapentine was roughly 4 times more potent in both mouse strains. These results reinforce the rationale for ongoing clinical trials to ascertain the highest well-tolerated doses of rifampin and rifapentine. This study also provides an important benchmark for the efficacy of the first-line regimen in C3HeB/FeJ mice, a strain in which the lung lesions observed after M. tuberculosis infection may better represent the pathology of human tuberculosis.

1 December 2007 in Inflammatory Bowel Diseases
Verified
Journal Article
Open access
PDF file
SRShervin Rabizadeh
Shervin Rabizadeh
KRKi-Jong Rhee
Ki-Jong Rhee
SWShaoguang Wu
Shaoguang Wu
DHDavid Huso
David Huso
CGChristine M. Gan
Christine M. Gan
CSCynthia L. Sears
Cynthia L. Sears
Background. Inflammatory bowel disease (IBD) is proposed to result from a dysregulated mucosal immune response to the colonic flora in genetically susce